390 results on '"Hadoux, Julien"'
Search Results
2. Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
3. Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor
4. Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study
5. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
6. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
7. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
8. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
9. Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE
10. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data
11. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma
12. Pneumocystis pneumonia in patients with Cushing's syndrome: A French multicenter retrospective study
13. New endpoints in adrenocortical carcinoma studies: a mini review
14. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival
15. Functional imaging in thyroid cancer patients with metastases and therapeutic implications
16. Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study
17. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives
18. Les stratégies de désescalade pour les cancers différenciés de la thyroïde
19. Impact of COVID-19 on healthcare organisation and cancer outcomes
20. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin
21. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network
22. D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
23. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors
24. Impact of expert review of histological diagnosis of papillary and follicular thyroid cancer
25. Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
26. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network.
27. Interference with VIP to distinguish between real and false VIPoma:national study from the French Endocrine Tumors Group
28. Effectiveness of temozolomide treatment in SDHx mutant and wildtype metastatic pheochromocytoma and paraganglioma - results of a European restrospective multicentre study
29. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
30. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer
31. Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors
32. La prise en charge des cancers médullaires de la thyroïde en 2024
33. Quelles avancées dans la prise en charge du carcinome anaplasique de la thyroïde en 2024 ?
34. Novel prognostic nomogram for predicting recurrence‐free survival in medullary thyroid carcinoma
35. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
36. Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.
37. Contributors
38. Postoperative Management of Differentiated Thyroid Cancer
39. ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration
40. Occult Contralateral Lateral Lymph Node Metastases in Unilateral N1b Papillary Thyroid Carcinoma
41. Transcriptional landscape of a RETC634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers
42. A diffuse pruriginous erythemato-squamous rash
43. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
44. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
45. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports
46. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study
47. Factors associated with survival in anaplastic thyroid carcinoma: A multi-center study from the ENDOCAN-TUTHYREF network
48. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
49. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids
50. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.